These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 28902084

  • 21. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
    Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.
    Cochrane Database Syst Rev; 2017 Sep 13; 9(9):CD008814. PubMed ID: 28901021
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pediatric Hodgkin's disease.
    Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ, Paris KJ, Silverman CL, Yashar CM.
    J Ky Med Assoc; 2004 Mar 13; 102(3):104-6. PubMed ID: 15067795
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, Bakhshi S.
    Leuk Lymphoma; 2017 Jul 13; 58(7):1617-1623. PubMed ID: 27919174
    [Abstract] [Full Text] [Related]

  • 26. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L.
    J Clin Oncol; 1994 Feb 13; 12(2):279-87. PubMed ID: 7509381
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
    Anselmo AP, Cavalieri E, Osti FM, Cantonetti M, De Sanctis V, Alfo M, Amadori S, Enrici RM.
    Anticancer Res; 2004 Feb 13; 24(6):4045-50. PubMed ID: 15736450
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India.
    Parambil BC, Narula G, Prasad M, Shah S, Shet T, Shridhar E, Khanna N, Laskar S, Gujral S, Sankaran H, Banavali S.
    Pediatr Blood Cancer; 2020 Feb 13; 67(2):e28058. PubMed ID: 31724304
    [Abstract] [Full Text] [Related]

  • 31. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.
    Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M, European Organisation for Research and Treatment of Cancer Lymphoma Group, and, Groupe d'Étude des Lymphomes de l'Adulte.
    Eur J Cancer; 2017 Aug 13; 81():45-55. PubMed ID: 28601705
    [Abstract] [Full Text] [Related]

  • 32. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
    Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM, Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).
    Ann Oncol; 2013 Dec 13; 24(12):3065-9. PubMed ID: 24121121
    [Abstract] [Full Text] [Related]

  • 33. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M.
    Int J Hematol; 2010 Dec 13; 92(5):713-24. PubMed ID: 21076995
    [Abstract] [Full Text] [Related]

  • 34. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
    Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P, Lymphoma Study Association (LYSA).
    Ann Oncol; 2014 Aug 13; 25(8):1622-8. PubMed ID: 24827123
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA, Wu Y, Prosnitz LR, Kim GJ, Beaven AW, Diehl LF, Kelsey CR.
    Int J Radiat Oncol Biol Phys; 2015 May 01; 92(1):54-9. PubMed ID: 25863754
    [Abstract] [Full Text] [Related]

  • 37. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K, Patil C, Anoop P, Reddy N, Anumula SK, Roopa SP, Golamari KR, Danthala M, Gunari P, Malipatil B, Rangarajan B, Udupa KS, Nandennavar M, Niraimathi K, Shewade HD.
    J Glob Oncol; 2019 Nov 01; 5():1-13. PubMed ID: 31834832
    [Abstract] [Full Text] [Related]

  • 38. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 39. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Lancet; 2015 Apr 11; 385(9976):1418-27. PubMed ID: 25539730
    [Abstract] [Full Text] [Related]

  • 40. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA.
    J Clin Oncol; 2004 Jan 01; 22(1):62-8. PubMed ID: 14657226
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.